SCHEMBL5263355

SCHEMBL5263355

NC(=O)/C(=C\c1c[nH]c2nc(NC(=O)c3ccccc3)ccc12)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
CCNA1 P78396 2/20 0.39
ADORA2A P29274 1/20 0.39
HDAC6 Q9UBN7 1/20 0.38
CDC7 O00311 1/20 0.38
MAP4K4 O95819 1/20 0.38
CDK8 P49336 1/20 0.38
DYRK1A Q13627 1/20 0.38
MELK Q14680 1/20 0.38
MAPK14 Q16539 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
STK17A Q9UEE5 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
HCAR3 P49019 1/20 0.38
HTR1A P08908 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262013 1.00 KMT2A (0.45) KMT2AMEN1NPC1RAB9ACCNA2
SCHEMBL5260835 0.95 GRM5 (0.44) KMT2AMEN1NPC1RAB9ACDC7
SCHEMBL5260838 0.95 GRM5 (0.44) KMT2AMEN1NPC1RAB9ACDC7
SCHEMBL5260557 0.94 MEN1 (0.40) KMT2AMEN1NPC1RAB9ACCNA2
SCHEMBL5260559 0.94 MEN1 (0.40) KMT2AMEN1NPC1RAB9ACCNA2
SCHEMBL5261407 0.92 PDE10A (0.37) KMT2AMEN1NPC1RAB9ACDK2
SCHEMBL5264201 0.92 PDE10A (0.37) KMT2AMEN1NPC1RAB9ACCNA2
SCHEMBL5261405 0.92 PDE10A (0.37) KMT2AMEN1NPC1RAB9ACDK2
SCHEMBL5264205 0.92 PDE10A (0.37) KMT2AMEN1NPC1RAB9ACCNA2
SCHEMBL5260183 0.91 KMT2A (0.39) KMT2AMEN1NPC1RAB9AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 KMT2A 1011/4885MEN1 3262/4885NPC1 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.